Angiotensin II induces calcium release in a subpopulation of single ovarian (granulosa) cells

Flores, Jorge A.; Veldhuis, Johannes D.; Leong, Denis A.

doi:10.1016/0303-7207(91)90199-3

Cited by 17 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the classical mechanism of action of GnRH implies stimulation of adenylate cyclase and cAMP production [Leung and Steele, 1992], the regulation of steroidogenesis by GnRH may be exerted through the stimulation of multiple pathways. The activation of PLCs and intracellular calcium increases have been involved in the action of gonadotropins in the ovary in several species, including the mouse, swine, hen and cow [Asem et al, 1987;Davis et al, 1987;Flores et al, 1991;Gudermann et al, 1992]. In other species, such as sheep and rats, GnRH did not induce calcium transients in the ovary [Davis et al, 1986;Wang et al, 1989;Wiltbank et al, 1989], although increases in InsP 3 formation after GnRH treatment were observed in these species [Jacobs et al, 1991;Davis et al, 1989].…”

Section: Discussionmentioning

confidence: 96%

Direct effect of a gonadotropin‐releasing hormone agonist on the growth of canine mammary tumour cells

Pagnini

Florio

Crispino

et al. 2002

J of Cellular Biochemistry

View full text Add to dashboard Cite

Gonadotropin-releasing hormone (GnRH) agonist exert "in vivo" an inhibitory action on the growth of hormone-dependent canine mammary tumours (Lombardi et al. [1999] J. Vet. Pharmacol Ther. 22(1):56-61). The present experiments have been performed "in vitro" in order to investigate the mechanisms involved in this direct antiproliferative action of GnRH agonists. In particular, the aim was to study whether these compounds might exert their antiproliferative effect by interfering with the stimulatory action of epidermal growth factor (EGF). To this purpose, the effects of GnRH agonist, Goserelin (GnRH-A), on the mitogenic action of EGF, on EGF-activated intracellular signaling mechanisms (intracellular calcium and nitric oxide production) as well as on ATP induced cell proliferation and signalling, and on the binding of EGF receptors have been evaluated in primary culture of canine mammary tumour cells. The results of these "in vitro" studies show that GnRH-A counteracts the mitogenic action of EGF and ATP, decreases the EGF/ATP-induced calcium signalling and reduces EGF binding, probably by means of NO-induced [Ca2+]i downregulation. These data suggest that GnRH agonists may inhibit the proliferation of the tumour cells by interfering with the stimulatory action of EGF.

show abstract